Related Experiment Video
Updated: Jan 12, 2026
Stem Cell Transplantation in an in vitro Simulated Ischemia/Reperfusion Model
Published on: November 5, 2011
Functional Efficacy of Intravitreal Dental Pulp Stem Cells versus Human Umbilical Vein Endothelial Cell-Conditioned
M Hossein Nowroozzadeh1, Mehrnoosh Maalhagh1, Fatemeh Sanie-Jahromi1
1Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Objective:
To evaluate the efficacy of intravitreal dental pulp stem cell-conditioned medium (DPSC-CM) versus human umbilical vein endothelial cell-CM (HUVEC-CM) in preserving retinal function after ischemia-reperfusion injury (IRI) in rabbits.
Design:
Experimental animal study.
Subjects:
Eighteen rabbits subjected to retinal IRI and randomized to receive intravitreal injections of DPSC-CM, HUVEC-CM, or balanced salt solution (BSS) (n = 6 per group).
Intervention:
After induction of retinal IRI, rabbits received intravitreal injections of DPSC-CM, HUVEC-CM, or BSS. Electroretinography (ERG) was performed 7 days postinjection to assess retinal function, measuring both dark-adapted (DA) and light-adapted (LA) responses.
Main Outcome Measures:
Preservation of a-wave and b-wave amplitudes on ERG as indicators of photoreceptor (PR) and bipolar cell function, respectively.
Results:
Both DPSC-CM and HUVEC-CM significantly preserved b-wave amplitudes in DA ERG responses compared to BSS (P < 0.05). Dental pulp stem cell-conditioned medium demonstrated superior preservation of a-wave amplitudes, indicating enhanced PR function. Both treatments also maintained LA ERG responses. Transient mucopurulent discharge in 2 DPSC-CM-treated rabbits and a localized posterior subcapsular opacity in one BSS-treated rabbit were observed; all resolved without sequelae.
Conclusions:
Intravitreal DPSC-CM and HUVEC-CM are effective in preserving retinal function after IRI, with DPSC-CM showing particular advantage in PR protection. These results support further investigation into DPSC-CM and HUVEC-CM as potential therapies for retinal ischemic conditions, such as retinal artery occlusion and anterior ischemic optic neuropathy.
Financial Disclosures:
The authors have no proprietary or commercial interest in any materials discussed in this article.
More Related Videos
10:24Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
08:10An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019